Drug Type Autologous CAR-T |
Synonyms- |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic lymphocytic leukaemia refractory | Phase 1 | United States | 26 Jun 2020 | |
Chronic lymphocytic leukaemia refractory | Phase 1 | United States | 26 Jun 2020 | |
Diffuse large B-cell lymphoma recurrent | Phase 1 | United States | 26 Jun 2020 | |
Diffuse large B-cell lymphoma recurrent | Phase 1 | United States | 26 Jun 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 1 | United States | 26 Jun 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 1 | United States | 26 Jun 2020 | |
Mantle cell lymphoma recurrent | Phase 1 | United States | 26 Jun 2020 | |
Mantle cell lymphoma recurrent | Phase 1 | United States | 26 Jun 2020 | |
Mantle cell lymphoma refractory | Phase 1 | United States | 26 Jun 2020 | |
Mantle cell lymphoma refractory | Phase 1 | United States | 26 Jun 2020 |